Human EGFRvIII CHO K1 Cell Line (High or Low Expression)

Only %1 left
Catalog #
78145
As low as $7,150 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant hEGFRvIII-CHO K1 cell line stably expressing full-length human EGFRvIII receptor (accession number NP_001333870). Surface expression of hEGFRvIII was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of hEGFRvIII expression (High and Low) to mimic different stages of cancer target cells with various EGFRvIII expression levels.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
ERBB cells, HER1 cell line, NISBD2 stable cells , PIG61 cells, epidermal growth factor receptor cell line, EGFR-vIII
Product Info
Storage and Usage
Citations
Host Cell Line
CHO-K1 cell line, Chinese Hamster Ovary, epithelial-like cells, adherent
Species
Human
Supplied As
Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Materials Required But Not Supplied

Materials Required for Cell Culture

Name Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3B BPS Bioscience #79529
UniProt #
P00533
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

The epidermal growth factor receptor (EGFR, ErbB-1, HER1) belongs to a family of receptor tyrosine kinases that includes three other closely-related members (HER2, HER3 and HER4). EGFR gene amplification, mutation and re-arrangement are frequently observed in primary glioblastoma multiforme (GBM). The most common EGFR variant in GBM, EGFRvIII, is characterized by a deletion of 267 amino acids in the extracellular domain, leading to a receptor that is unable to bind ligand yet is constitutively active. EGFRvIII enhances the tumorigenic potential of GBM by activating and sustaining mitogenic, anti-apoptotic, and pro-invasive signaling pathways.